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Biodegradable stents are an attractive alternative to self-expanding metal stents in the treatment of intestinal strictures. Biodegradable stent can be made
of biodegradable polymers and biodegradable metals (magnesium alloys). An overview on current biodegradable intestinal stents is presented. The future
trends and perspectives in the development of biodegradable intestinal stents are proposed. For the biodegradable polymer intestinal stents, the clinical trials
have shown promising results, although improved design of stents and reduced migration rate are expected. For the biodegradable magnesium intestinal
stents, results of preliminary studies indicate magnesium alloys to have good biocompatibility. With many of the key fundamental and practical issues
resolved and better methods for adjusting corrosion resistance and progressing biocompatibilities of magnesium alloys, it is possible to use biodegradable
intestinal stents made of magnesium alloys in hospital in the not too distant future.
& 2014 Chinese Materials Research Society. Production and hosting by Elsevier B.V. All rights reserved.
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Intestinal strictures are a common complication of enteral
diseases, including malignant and benign strictures. Malignant
strictures include documented malignant obstructions of the
duodenum, small bowel, or colorectum. Common malignan-
cies include metastatic disease to the duodenum or proximal
jejunum, unresectable cholangiocarcinoma. Benign causes of
obstruction include Crohn's disease and anastomotic strictures.
Intestinal stents are deﬁned as stents deployed within the small
bowel and colon. Metal and plastic stents are useful for
treatment of both malignant and benign strictures or ﬁstulas
throughout the intestinal tract; however, the use of these stents
is associated with several common problems including new10.1016/j.pnsc.2014.08.008
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and repetitive endoscopic procedures [1]. Uncovered metallic
stents induce early mucosal hyperplastic reaction; covered
metallic and plastic stents are associated with a higher risk of
migration and lower ﬂexibility and shorter/lower radial force
[2]. An ideal stent for benign stenoses would be one that has a
large diameter, high expansion ratio, axial ﬂexibility, optimal
delivery system, withstands ingrowth, maintains luminal integrity,
does not cause stent-induced mucosal or parenchymal injury, and
does not need a repeat endoscopy for removal [3]. Recently,
signiﬁcant advances have been made in the development of
biocompatible and biodegradable materials for medical applica-
tions. To overcome the shortcomings of permanent metal and
plastic stents, biodegradable stents have been developed. The
prolonged dilatory effect before stent absorption and the pro-
gressive stent degradation could represent a more favorable
solution for patients with benign strictures refractory to standard
dilation therapy compared with self-expandable metal and plastic
stents, as already shown for esophageal strictures [4,5]. Fig. 1Elsevier B.V. All rights reserved.
Fig. 1. The diagram of placement process and mechanical function of intestine stent: (a) is the cross-section of the deﬂated balloon catheter and closed stent inserted
into the narrowed intestine; (b) is a balloon inﬂated, expanding the stent and compressing the tumor to restore the lumen size of the intestine, the stent can be
adhesive to the intestinal mucosa; and (c) is the compressed tumor and stent-widened intestine; IP is the intestinal pressure because of the solid feces and movements
of intestine, and IAP is the intra-abdominal pressure concealed within the abdominal cavity [32].
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with stenosis.
2. Types of biodegradable materials
2.1. Biodegradable polymers
A biomaterial is deﬁned as any natural or synthetic
substance engineered to interact with biological systems in
order to direct medical treatment [6]. Biomaterials must be
biocompatible meaning which they perform their function with
an appropriate host response [7]. Because degradable polymers
are able to be broken down and excreted or resorbed without
removal or surgical revision, these biomaterials are of utmost
interest. Although natural polymers like collagen have been
used biomedically for thousands of years, research into
biomedical applications of synthetic degradable polymers is
relatively new, starting in the 1960s [7]. Biodegradable
synthetic polymers offer a number of advantages over other
materials for developing scaffolds in tissue engineering. The
key advantages include the ability to tailor mechanical proper-
ties and degradation kinetics to suit various applications. In
addition, the main advantages of synthetic polymers are good
biocompatibility, low coefﬁcients of friction, easy processing
and workability, ability to change surface chemically and
physically, and ability to immobilize cells or biomolecules
within them or on the surface [8]. Biodegradable synthetic
polymers such as poly(glycolic acid), poly(lactic acid) and
their copolymers, poly(p-dioxanone), and copolymers of
trimethylene carbonate and glycolide have been used in a
number of clinical applications [9]. The major applications
include resorbable sutures, stents, drug delivery systems and
orthopedic ﬁxation devices such as pins, rods and screws [9].2.2. Biodegradable magnesium alloys
Traditional metallic materials require minimal corrosion
reaction in the body. Over the last decade, a large increase
in publications on biodegradable metallic materials has been
recorded in both scientiﬁc journals and patent databases [10].
Biodegradable metals are deﬁned as metals that are expected to
corrode gradually in vivo, with an appropriate host response
elicited by released corrosion products, then dissolve comple-
tely upon fulﬁlling the mission to assist with tissue healing
with no implant residues [11]. Currently investigated biode-
gradable metals are mainly magnesium (Mg) and iron (Fe)
based alloys, and magnesium alloys are the most intensively
studied. Biodegradable magnesium alloys seem to be the
suitable biomedical degradable materials. Firstly, magnesium
and its alloys are susceptible to dissolution in aqueous
solutions, particularly in those containing chloride ion electro-
lytes because of their very low corrosion potential [12,13].
Secondly, Young's modulus of magnesium alloys is about
45 GPa, which is much closer to that of natural bone (15–
20 GPa) [14] than the currently used biomedical metals, such
as stainless steel and Nitinol [15]. Therefore the stress
shielding effect can be avoided. Thirdly, Mg2þ is an essential
element and presents in large amount (the fourth most
abundant cation) in the human body. The daily intake of Mg
for a normal adult is about 300–400 mg and redundant
magnesium cations can be harmlessly and efﬁciently excreted
in the urine [16]. Therefore, recently, the study of degradable
magnesium alloys has become one of the most revolutionary
research topics at the forefront of biomaterials [10,17–20].
Unfortunately, due to this high corrosion rate of magnesium
alloys, degradation occurs before the end of healing process.
This has become the main limitations of magnesium alloys in
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(ultra-ﬁne grain, bulk metallic glass) and surface modiﬁcation
are effective strategies to improve the corrosion resistance of
magnesium alloys [22]. The application of biodegradable
magnesium alloy mainly focuses on cardiovascular stents
and orthopedic implants. Mg-based absorbable metal stent
(AMS, Biotronik, Bülach, Switzerland) are reported to be
associated with a high procedural success rate and are well
tolerated within different kinds of blood vessels, such as
coronary [23,24], pulmonary arteries [25], and lower limb
vessels [26,27]. With modiﬁcations of chemical composition
and strut design to AMS, as well as fast degradable polymer-
coating carrier with an anti-proliferative drug, the drug-eluting
absorbable metal scaffold (DREAMS, Biotronik, Bülach,
Switzerland) showed an increased radial force, a slower
degradation rate and promising clinical and angiographic
performance in a prospective, multicentre, ﬁrst-in-man trial
(BIOSOLVE-1) [28]. MAGNEZIXs Compression Screw
(Syntellix AG Schiffgraben 11, 30159 Hannover, Germany)
is a compression screw which can be used for ﬁxing small
bones and bone fragments, which is the ﬁrst magnesium screw
product that gets a CE mark. Results of a clinical pilot study
revealed that clinically the MAGNEZIXs Compression Screw
is equivalent to titanium screw in hallux valgus surgery [29].3. In vitro and animal test of biodegradable intestinal
stents
3.1. Biodegradable polymer intestinal stents
Zilberman et al. [30] investigated the mechanical properties of
poly(L-lactide) (PLLA), polydioxanone (PDS), and glycolide-co-
ε-caprolactone (PGACL) ﬁbers and stents. Initially, PLLA
demonstrated a very high tensile strength (967 MPa) and modulus
(5000 MPa) and a moderate ultimate strain (50%), PDS ﬁbersFig. 2. The morphology changes of PDS stents in vitro degradation: where (a)–(f) p
prepare PDS samples for SEM after 16 weeks, as the PDS materials were brokenshowed moderate tensile strength (583 MPa) and modulus
(367 MPa) and high ductility (161%), and PGACL exhibited
high tensile strength (721 MPa) and ductility (151%) and
moderate modulus (477 MPa). Degradation studies of these ﬁbers
indicate that PLLA undergoes slow degradation and can therefore
preserve good mechanical properties for 24 weeks. PDS partially
preserves its mechanical properties for 6 weeks, whereas the
PGACL ﬁber totally loses its strength after 3 weeks. PDS is a
semicrystalline, biodegradable polymer that belongs to the
polyester family. PDS monoﬁlament is commercially absorbable
surgical suture. It degrades by random hydrolysis of its molecule
ester bonds. The degradation accelerates by low pH. The
degradation product—glyoxylic acid—is the primary precursor
of oxalic acid and is an intermediate in the conversion of glycolic
acid to glycine. None of degradation products or intermediates is
harmful [31]. The degradation process occurs in two stages. The
ﬁrst involves amorphous regions of the matrix, the second the
crystalline areas of the polymer [31,32]. Due to the fact that
mechanical and physical properties largely depend on the
presence of the crystalline areas, the effect of the degradation is
not linear. The stent material is partly absorbed and partly travels
through the gastrointestinal system. Li et al. [32] found the weft-
knitted PDS stent maintained more than 60% of its original radial
force above 12 weeks in PBS. No apparent changes of the stent
were found within 8 weeks, while small cracks were observed
after 12 weeks, as shown in Fig. 2.3.2. Biodegradable magnesium intestinal stents
To date, there is no report about prototype of biodegradable
magnesium intestinal stents. This is probably due to the limited
ductility and poor workability at room temperature resulting
from its hexagonal crystal lattice, which leads to the great
challenge of processing magnesium wires with small diameter
for knitting of stent. However, attempts were carried out andhotographs are stents degraded at 0, 2, 4, 8, 12, and 16 weeks. It was difﬁcult to
down into very small and fragile pieces after having vacuum dry [32].
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cells and tissues were evaluated. Mg tubes were investigated
as connectors of intestine anastomosis as early as 1900s.
Chlumský [33] successfully used of Mg connectors in humans
and it took 2–4 weeks for complete breakdown, depending on
the anatomical location and the size of the implant. Deng [34]
found the average degradation rate of the AZ91D magnesium
alloy in artiﬁcial intestinal juice was 0.33 mg/cm2 day and it
has good biocompatibility, no mutagenicity and no pyrogen
reaction. Recent studies [35,36] indicated that the levels of
apoptosis in intestinal epithelial cells (IEC-6) cultured in 100%
Mg–6Zn alloy extracts were signiﬁcantly higher than those in
60% and 20% extracts, and the IEC-6 cells displayed better
cell functions in 20% extract of the Mg–6Zn alloy extracts,
compared to the 100% or 60% extracts, which indicated the
control of the corrosion rate is very essential. The biodegrad-
able Mg–6Zn alloy samples are implanted around the cecum
[37,38]. Results showed that magnesium–zinc alloy started to
degrade at the third week (Fig. 3). Results of histological
evaluation revealed that both the Mg–6Zn alloy and titanium
(compared with the negative control) did not bring about
organic damage to vital organs (Fig. 4). Superior to the
Ti–3Al–2.5V alloy, the Mg–6Zn alloy enhanced the expres-
sion of transforming growth factor-β1 in healing tissue, and
promoted the expression of both the vascular endothelial
growth factor and the basic ﬁbroblast growth factor, which
helped angiogenesis and healing. The Mg–6Zn alloy reduced
the expression of the tumor necrosis factor (TNF-α) at different
stages and decreased inﬂammatory response, which may have
been related to the zinc inhibiting TNF-α. In general, the Mg–
6Zn alloy performed better than Ti–3Al–2.5V at promoting
healing and reducing inﬂammation [38]. Cao et al. [39]Fig. 3. X-ray ﬁlms of cecum implanted titanium stick in a rat: (A) ﬁrst week; (B)
(F) third week [37].explored the safety and feasibility of biodegradable magne-
sium alloy stapler for gastrointestinal anastomosis in beagle
dogs. There is no signiﬁcant difference between the magne-
sium group and the control (titanium alloy) group, and the
anastomosis was healed well with no dramatic inﬂammatory
cell inﬁltration was observed. The degradation of magnesium
alloy did not harm the important organs (liver, kidney, heart,
brain and spleen).
4. Clinical trials of biodegradable intestinal stents
Dedicated intestinal stents are not available by far and there
is currently no published clinical experience with intestinal
stents of magnesium alloys. Fig. 5 shows three designs of
biodegradable BD stents (ELLA-CS, Hradec Kralove, Czech
Republic), which is originally designed for use in the treatment
of esophageal stenosis. This BD stent has been successfully
applied in the treatment of benign conditions in the lower
gastrointestinal tract. The stents are manufactured from woven
PDS monoﬁlament. They are available with trunk diameters of
18–25 mm, typically with both ends ﬂaring to 23–31 mm as
shown in Fig. 5(a), and are in different lengths from 60 to
135 mm. Its degradation can be accelerated by a low ambient
pH. The stent integrity and the radial force of the stent are
maintained for 6–8 weeks following implantation and there is
an extended period of dilation in comparison to conventional
methods. Stent disintegration occurs 11–12 weeks following
implantation and there is no need for removal. Flared ends
reduced migration rates and radiopaque markers at both stent
ends assist with accurate positioning [40]. The standard
delivery system for esophageal implantation has an active
length of 75 cm and can only be used for intestinal stricturessecond week; (C) third week; Mg–6Zn alloy: (D) ﬁrst week; (E) second week;
Fig. 4. Histological evaluation of (a) liver, (b) kidney, (c) cecum after implantation of titanium and Mg–6Zn stick into the cecum of a rat for (A) 1st week; (B) 2nd
week; (C) 3rd week; and (D) 4th week (hematoxylin–eosin staining, 100 ) [37].
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accomplished by use of a custom made introducer inserted into
an overtube after endoscope removal [41]. Up to now, BD
stent is the only biodegradable stent that has been applied in
the treatment of stricturing Crohn's disease [2,3,41], anasto-
motic colorectal strictures [31,42–44], and postsurgical colonic
ﬁstulas [44]. The cases and case series are summarized in
Table 1.
4.1. Biodegradable stent for the treatment of benign stenoses
in Crohn's disease
Strictures are a common complication of Crohn's disease,
occurring in 1/3 of patients after 10 years of disease [41]. Rejchrt
et al. [2] were the ﬁrst who introduced this biodegradable stent forFig. 5. Biodegradable BD stents (ELLA-CS, Hradec Kralove, Czech Republic) wov
at both ends; design (b) with a waved shape; and design (c) without ﬂared ends.
detachable olive is shown below [3].
Table 1
Cases series evaluating the outcomes of biodegradable stents for intestinal and col
Author Year Type of study Indication n
Rejchrt et al. [2] 2009 CS Stricturing CD 3
Rejchrt et al. [3] 2011 CS Stricturing CD 11
Rodrigues et al. [41] 2013 CR Stricturing CD 1
Toth et al. [56] 2011 CR PS 1
Janík et al. [42] 2011 CS PS 3
Belvedere et al. [57] 2012 CS PS 1
Repici et al. [31] 2013 CS PS 11
Pérez et al. [44] 2012 CS PS and ﬁstula 10
CR: Case report; CS: Case series; CD: Crohn's disease; PS: Postsurgical stricturesthe treatment of small and large intestinal stenoses in 2009.
Insertion of biodegradable stents was successful in all three patients
with tight benign intestinal stenoses as a complication of Crohn's
disease. No stent migration or major complications were observed.
In one case, two months after implantation, the stent was cutoff
endoscopically and discharged spontaneously because the proximal
ﬂared end of the stent came into contact with the intestinal wall
(without stent migration) and caused intermittent transit obstruction.
A case series including 11 patients with stenosing Crohn's disease
were reported in 2011 [3]. Biodegradable stent with three different
designs were used, as shown in Fig. 3. Endoscopic insertion of the
stents was successful at the ﬁrst attempt in all patients except one.
Endoscopic views of a typical stenosis before and after biodegrad-
able stent insertion and corresponding ﬂuoroscopic images are
shown in Figs. 6 and 7, respectively. Subsequent follow-up was foren from polydioxanone ﬁlament with three different designs: design (a), ﬂared
An introducer sheath loaded with a biodegradable stent and a balloon with a
onic strictures.
Outcome Complications
66% symptom-free end FU 0%
33% Intermittent transit obstruction
Technical success rate 91% Stent migration, 27%
Symptom-free FU (12–27 weeks) 64%
Time to stent degradation was 4 months
Symptom-free end FU (16 months) 0%
Symptom-free end FU (24 months) hyperplastic tissue reaction
Stoma reversal 66% 0%
Completely degradation after 4 months
0%
45% symptom-free end FU (16 months) Stent migration,, 36%
66% symptom-free end FU Stent migration, 10%
; FU: Follow-up.
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Stent migration was recorded in three patients. In two of them,
waved stents, design (b) in Fig. 3, had been used, which indicated
design (b) is defective. Results showed that mucosal overgrowth
(epithelial hyperplasia) was not observed in any of the patients
during the follow-up period. These were the only two reports of the
use of biodegradable stents in the small bowel and proximal
large bowel.Fig. 6. Endoscopic views of a typical stenosis before and after biodegradable stent
ulcer. (b) A deployed biodegradable stent in the stenotic anastomosis immediately
Fig. 7. Fluoroscopic images before and after biodegradable stent insertion from the
colon anastomosis. (b) Balloon dilation of the stenotic area. The distal margin of the
with three radio-opaque markers (arrowheads), in situ immediately after its deploym
metallic clip (arrow). (d) Appearance of the biodegradable stent at the end of the pRodrigues et al. [41] reported the case of a 33-year-old patient
with long-standing Crohn's disease who developed a ﬁbrotic
stricture of the sigmoid too long to be amenable to balloon
dilation. The use of a biodegradable polydioxanone stent was
chosen to avoid surgery. The results showed that combined
endoscopic and ﬂuoroscopic placement of the stent was technically
simple, safe and clinically successful, and no recurrence of
obstructive symptoms occurred during a 16-month follow-up [41].insertion. (a) Anileo-ascending colon anastomosis with a tight stenosis and
after its insertion [3].
same patient as shown in Fig. 6. (a) Stenosis (arrow) of the ileo-ascending
anastomosis is marked with a metallic clip (arrow). (c) Biodegradable stent,
ent from the introducer. The distal margin of the stenosis is marked with a
rocedure [3].
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colorectal strictures and ﬁstulas
Strictures following colorectal surgery occur in 1.5–8% of
patients [45]. Various factors are associated with the deve-
lopment of an anastomotic stricture like technical errors in
confectioning the suture, poor blood supply, inﬂammation
following small anastomotic leaks or radiotherapy [31]. Eleven
patients (7 males, mean age 62.378.5 years) with postsurgical
benign strictures located within 20 cm from anal verge,
refractory to mechanical or pneumatic dilation (at least 3
sessions) were treated with the BD stents [31]. Patients with
concomitant presence of a ﬁstula, the suspicion of malignancy,
diverticular stenosis, previous stent placement, and a location
of the stricture too close to the anus (o5 cm) were deemed
unﬁt for BD stenting. Results showed that technical success
was achieved in all the patients. Stent migration was observed
in four patients within the ﬁrst 2 weeks after stent placement
and was followed by recurrence of stricture and obstructive
symptoms in all the cases. Among the seven patients who
completed the process of stent biodegradation, ﬁve of them
had complete resolution of the stricture and relief of symp-
toms. Two of 11 patients required surgical treatment during the
follow-up period (mean 19.8 (range 42–15) months). The
overall success rate of the BD stent was only 45% [31].
Endoscopic follow-up showed only a mild hyperplastic reac-
tion, which resolved after stent degradation in the majority of
patients. The authors considered the suboptimal efﬁcacy of the
BD stent is related more with the early migration rather than to
an intrinsic failure in dilating the stricture. There are three
factors that contribute to the early migration: the nondedicated
design of the stent (stents for colonic strictures require a larger
caliber than esophageal stents), the predilatation and passage
of stools, and the laxative use. Dedicated stents with large
diameter and antimigration ﬁndings could potentially improve
the outcome of patients with refractory benign colorectal
strictures [31]. Stent migration was not observed in other
reports which included limited number of patients. Toth et al.
[43] reported a case with a benign stricture in a colorectal
anastomosis, treated with a biodegradable stent. The stent
position was monitored 6 weeks after deployment and shown
to be partially reabsorbed. The patient was still asymptomatic
and a colonoscopy revealed complete biodegradation of the
stent 5 months later. However, a hyperplastic tissue reaction
was observed at distal part of the colorectal stricture. At this
time, the lumen had reduced to 8 mm and was therefore dilated
up to 18 mm. A follow-up was performed 2 years later, which
revealed that the patient had no clinical symptoms although
the size of the lumen had reduced [43]. In another study,
biodegradable stents were inserted into three male patients
(median age 66) who developed benign strictures after radio-
therapy and resection of a recto-sigmoid carcinoma [42]. The
results showed that all stents were placed successfully without
complications after pre-dilatation to 20 mm under ﬂuoroscopic
guidance. Stent degradation occurred in all patients 4–5
months following implantation, and long-term anastomotic
patency was demonstrated in all [42]. This allowed reversalof the colostomy and physiological defecation in two patients.
Reversal was not undertaken in one due to subsequent
development of liver metastases. No stent migration or
occlusion occurred [42]. It was concluded that biodegradable
stents can maintain an adequate lumen across anastomotic
strictures resistant to balloon dilatation. They seem to allow
stricture re-modeling resulting in maintained dilatation after
degradation [42].
In 2012, one study was performed to evaluate the safety of
biodegradable stents for the treatment of colonic strictures and
ﬁstulas [44]. They analyzed the results from 10 patients with
either a postsurgical colorectal stricture (n¼7) or rectocuta-
neous ﬁstula (n¼3) treated with the biodegradable SX-ELLA
esophageal stent [44]. In the patients with rectocutaneous
ﬁstulas (n¼2), suture dehiscence (n¼1), and postsurgical
cloaca with stricture (n¼1), the covered stents that had a
polyethylene internal coating were used. The results showed
that stents were successfully placed in nine patients, although
early migration subsequently occurred in one. Placement was
impossible in one patient due to deformity of the area and the
fact that the stricture was approximately 30 cm from the anus.
The ﬁstulas were successfully closed in all patients, although
symptoms reappeared in one patient. Breakage of the poly-
ethylene coating occurred in one of the coating stents. In the
six patients who received stents for strictures, symptoms
resolved in ﬁve; in the remaining patient, the stent migrated
shortly after the endoscopy [44]. It was concluded that
treatment of colonic strictures and rectocutaneous ﬁstulas with
biodegradable stents is an effective alternative in the short-to-
medium term. The stent does not have to be removed and is
subject to very few complications [44].
The above cases indicated that the technical success of BD
stent in intestinal insertion is high, except for proximal
stenoses and in patients with considerable deformity and
angulations. Early stent migration rate is about 20%, which
is the main reason of clinical failure. The early migration
can be solved using cyanoacrylate, with a clip placement in
the upper ﬂare or by improvements in stent design. Severe
mucosal hyperplastic reaction resulting in obstruction after
biodegradable stenting has been documented in esophageal
strictures [46,47] but not in intestinal strictures thus far.
5. Concluding remarks
Biodegradable stents overcome some of the problems
encountered with self-expanding metal stents. The primary
advantage of biodegradable stents over self-expandable metal-
lic stents is that removal is not required. Biodegradable
polymer stents has been successfully employed in the treat-
ment of benign esophageal strictures [5,48–50], malignant
esophageal strictures [51], and esophageal perforation or
anastomotic leak [52]. There are, however, limited data
available on their use in the intestinal tract. The clinical
experience with currently the only biodegradable stents (BD
stents) for endoscopic placement, made of poly-dioxanone,
have shown promising results. Intestinal stents with improved
design and reduced migration are expected. Clinical trials
Z. Wang et al. / Progress in Natural Science: Materials International 24 (2014) 423–432 431including larger number of patients and longer follow-ups will
be necessary. The price of these nowadays is also an important
limitation [8].
Compared to biodegradable polymer, the development of
biodegradable magnesium alloys is still in its infancy. Never-
theless, besides cardiovascular stents and orthopedic implants,
preliminary attempts of biodegradable Mg-based devices have
been made in many areas such as esophageal stent for infants
[53], biliary stents [54] and ureteral stents [55]. With many of
the key fundamental and practical issues resolved and better
methods for adjusting corrosion resistance and progressing
biocompatibilities of magnesium alloys, it is possible to use
biodegradable intestinal stents made of magnesium alloys in
hospital in the not too distant future.
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